This protocol addresses Behçet's syndrome presenting with arthritis — a recognised musculoskeletal manifestation of the disease that requires structured clinical management to control joint inflammation and reduce recurrence.
Arthritis is a significant feature of Behçet's syndrome and warrants a clear, stepwise treatment approach. Acute episodes are managed with initial therapy; when joint involvement becomes recurrent or persistent, the clinical pathway calls for escalation beyond the first step.
For recurrent or chronic arthritis in Behçet's syndrome, established immunomodulatory options are available — the structured protocol defines which agents to consider and when.
DOI: 10.1136/annrheumdis-2018-213225
Colchicine should be the initial treatment in BS patients with acute arthritis.
Azathioprine, interferon-alpha or TNF-alpha inhibitors should be considered in recurrent and chronic cases.
View source ↗